Literature DB >> 8977444

A cysteine-containing truncated apo A-I variant associated with HDL deficiency.

K Moriyama1, J Sasaki, Y Takada, A Matsunaga, J Fukui, J J Albers, K Arakawa.   

Abstract

We identified a 50-year-old Japanese woman with a novel mutation in the apolipoprotein (apo) A-I gene causing high-density lipoprotein (HDL) deficiency. The patient had extremely low HDL cholesterol and apo A-I levels (0.14 mmol/L and 0.8 mg/dL, respectively) but no evidence of coronary heart disease. However, she had bilateral xanthomas of the Achilles tendon, elbow, and knee joint as well as corneal opacities. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of serum followed by immunoblotting revealed that the patient's apo A-I had a lower molecular weight (24,000) than normal apo A-I. A partial gene duplication encompassing 23 nucleotides was found by DNA sequence analysis, resulting in a tandem repeat of bases 333 to 355 from the 5' end of exon 4. This tandem repeat caused a frameshift mutation with premature termination after amino acid 207. The frameshift gives rise to a predicted protein sequence that contains two cysteines. We designated this mutant as apo A-ISasebo. Apo A-ISasebo formed heterodimers with apo A-II and apo E in the patient's plasma and was associated with both the low-density lipoprotein and HDL fractions. The patient's cholesterol esterification rate and lecithin-cholesterol acyltransferase activity were reduced to about 30% of normal, although specific enzyme activity was unaffected, suggesting that it remained functionally normal. In addition, cholesteryl ester transfer activity was reduced to about half of normal. Thus, apo A-ISasebo was associated with complex derangements of lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977444     DOI: 10.1161/01.atv.16.12.1416

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice.

Authors:  Sean A Wiltshire; Eduardo Diez; Qianqian Miao; Marie-Pierre Dubé; Mireille Gagné; Olivier Paquette; Ronald G Lafrenière; Momar Ndao; Lawrence W Castellani; Emil Skamene; Silvia M Vidal; Anny Fortin
Journal:  Physiol Genomics       Date:  2012-07-17       Impact factor: 3.107

Review 2.  HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.

Authors:  Esther Y Lee; Peter T Klementowicz; Robert A Hegele; Bela F Asztalos; Ernst J Schaefer
Journal:  J Clin Lipidol       Date:  2012-11-17       Impact factor: 4.766

3.  A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.

Authors:  Judit Cubedo; Teresa Padró; Maisa García-Arguinzonis; Gemma Vilahur; Inka Miñambres; Jose María Pou; Juan Ybarra; Lina Badimon
Journal:  J Lipid Res       Date:  2015-07-13       Impact factor: 5.922

4.  Re-sequencing of the APOAI promoter region and the genetic association of the -75G > A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population.

Authors:  Suzanne A Al-Bustan; Ahmad E Al-Serri; Babitha G Annice; Majed A Alnaqeeb; Ghada A Ebrahim
Journal:  BMC Med Genet       Date:  2013-09-12       Impact factor: 2.103

Review 5.  Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative Diseases.

Authors:  Ian James Martins
Journal:  Int J Mol Sci       Date:  2015-12-10       Impact factor: 5.923

6.  Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design.

Authors:  Hayato Tada; Tomoyuki Kurashina; Masatsune Ogura; Misa Takegami; Yoshihiro Miyamoto; Hidenori Arai; Mariko Harada-Shiba; Shun Ishibashi
Journal:  J Atheroscler Thromb       Date:  2021-10-22       Impact factor: 4.394

Review 7.  Structural Insights into High Density Lipoprotein: Old Models and New Facts.

Authors:  Valentin Gogonea
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.